Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SCPH Stock Forecast 2025-2026
$3.51
Current Price
$181.08M
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to SCPH Price Targets
+613.3%
To High Target of $25.00
+256.6%
To Median Target of $12.50
+213.8%
To Low Target of $11.00
SCPH Price Momentum
+9.0%
1 Week Change
+35.0%
1 Month Change
-0.3%
1 Year Change
-0.8%
Year-to-Date Change
-38.0%
From 52W High of $5.65
+80.7%
From 52W Low of $1.94
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Scpharmaceuticals (SCPH) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on SCPH and similar high-potential opportunities.
Latest SCPH Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, SCPH has a bullish consensus with a median price target of $12.50 (ranging from $11.00 to $25.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $3.51, the median forecast implies a 256.6% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Ken Cacciatore at Cowen & Co., projecting a 613.3% upside. Conversely, the most conservative target is provided by Roanna Ruiz at SVB Leerink, suggesting a 213.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SCPH Analyst Ratings
6
Buy
0
Hold
0
Sell
SCPH Price Target Range
Low
$11.00
Average
$12.50
High
$25.00
Current: $3.51
Latest SCPH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SCPH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 20, 2025 | Maxim Group | Naz Rahman | Buy | Maintains | $12.00 |
| Mar 20, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Mar 7, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Mar 3, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Nov 14, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $12.00 |
| Aug 19, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| May 15, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Mar 14, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Sep 7, 2023 | Craig-Hallum | Chase Knickerbocker | Buy | Initiates | $20.00 |
| Aug 11, 2023 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Aug 2, 2023 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Jul 19, 2023 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Jun 8, 2023 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| May 11, 2023 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| May 11, 2023 | Maxim Group | Naz Rahman | Buy | Maintains | $20.00 |
| Mar 23, 2023 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Jan 27, 2023 | SVB Leerink | Roanna Ruiz | Outperform | Maintains | $13.00 |
| Dec 1, 2022 | Cowen & Co. | Ken Cacciatore | Outperform | Initiates | $25.00 |
| Nov 10, 2022 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $18.00 |
ScPharmaceuticals Inc. (SCPH) Competitors
The following stocks are similar to Scpharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SCPH
Scpharmaceuticals
mkt cap
144.82M
ScPharmaceuticals Inc. (SCPH) Financial Data
ScPharmaceuticals Inc. has a market capitalization of $181.08M with a P/E ratio of -1.8x. The company generates $41.98M in trailing twelve-month revenue with a -216.2% profit margin.
Revenue growth is +92.6% quarter-over-quarter, while maintaining an operating margin of -151.1% and return on equity of -934.0%.
Valuation Metrics
Market Cap
$181.08M
Enterprise Value
$170.78M
P/E Ratio
-1.8x
PEG Ratio
-4.7x
Price/Sales
4.3x
Growth & Margins
Revenue Growth (YoY)
+92.6%
Gross Margin
+70.5%
Operating Margin
-151.1%
Net Margin
-216.2%
EPS Growth
+92.6%
Financial Health
Cash/Price Ratio
+31.3%
Current Ratio
5.5x
Debt/Equity
-10.2x
ROE
-934.0%
ROA
-49.2%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
ScPharmaceuticals Inc. (SCPH) Business Model
About ScPharmaceuticals Inc.
What They Do
Develops innovative treatments for heart failure.
Business Model
The company focuses on developing and commercializing user-friendly therapies for chronic conditions, particularly those that can be administered at home. By simplifying the drug delivery process, ScPharmaceuticals reduces the need for hospital visits, thereby generating revenue through the sale of its innovative pharmaceutical products.
Additional Information
ScPharmaceuticals has developed advanced subcutaneous formulations for self-administration, improving patient comfort and adherence to treatment plans. This innovation not only enhances patient care but also offers potential cost savings to healthcare systems globally, particularly in the treatment of acute heart conditions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
162
CEO
Mr. John H. Tucker
Country
United States
IPO Year
2017
Website
www.scpharmaceuticals.comScPharmaceuticals Inc. (SCPH) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates
scPharmaceuticals (SCPH) delivered earnings and revenue surprises of -25.93% and 3.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
May 14, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
scPharmaceuticals shares fell 37% over three years and 11% in 2025. Furoscix may reduce hospital readmissions, with Medicare redesign and label expansion expected to drive future growth.
Why It Matters
scPharmaceuticals' stock decline highlights investor concerns, but Furoscix's potential to reduce hospitalizations and upcoming growth catalysts may signal a turnaround opportunity.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
scPharmaceuticals Inc. will hold its Q1 2025 Earnings Conference Call on May 14, 2025, at 4:30 PM ET. Key executives and analysts will participate.
Why It Matters
The earnings call will provide insights on scPharmaceuticals' financial performance and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
9 days ago
Quick Summary
scPharmaceuticals reported Q1 2025 net revenue of $11.8M from FUROSCIX. The drug was launched for Chronic Kidney Disease in April 2025, with an autoinjector submission planned for Q3 2025. Cash on hand is $57.5M.
Why It Matters
The substantial revenue from FUROSCIX and its expansion into Chronic Kidney Disease indicate growth potential. The upcoming sNDA submission could enhance market position and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ScPharmaceuticals, Inc. (SCPH) reported a quarterly loss of $0.34 per share, missing the Zacks Consensus Estimate of a $0.27 loss, compared to a loss of $0.36 per share a year earlier.
Why It Matters
ScPharmaceuticals' larger-than-expected quarterly loss signals potential operational challenges, which may impact investor confidence and affect stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025
16 days ago
Quick Summary
Management will host a conference call and webcast on May 14, 2025, at 4:30 p.m. ET, following the market close.
Why It Matters
The conference call indicates upcoming financial results or strategic updates, potentially impacting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
scPharmaceuticals Inc. (Nasdaq: SCPH) will have CEO John Tucker speaking at upcoming investor conferences, focusing on innovations in cardiorenal healthcare.
Why It Matters
John Tucker's participation in investor conferences signals potential insights into scPharmaceuticals' future strategies and innovations, impacting investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SCPH Stock
What is ScPharmaceuticals Inc.'s (SCPH) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, ScPharmaceuticals Inc. (SCPH) has a median price target of $12.50. The highest price target is $25.00 and the lowest is $11.00.
Is SCPH stock a good investment in 2025?
According to current analyst ratings, SCPH has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.51. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SCPH stock?
Wall Street analysts predict SCPH stock could reach $12.50 in the next 12 months. This represents a 256.6% increase from the current price of $3.51. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is ScPharmaceuticals Inc.'s business model?
The company focuses on developing and commercializing user-friendly therapies for chronic conditions, particularly those that can be administered at home. By simplifying the drug delivery process, ScPharmaceuticals reduces the need for hospital visits, thereby generating revenue through the sale of its innovative pharmaceutical products.
What is the highest forecasted price for SCPH ScPharmaceuticals Inc.?
The highest price target for SCPH is $25.00 from Ken Cacciatore at Cowen & Co., which represents a 613.3% increase from the current price of $3.51.
What is the lowest forecasted price for SCPH ScPharmaceuticals Inc.?
The lowest price target for SCPH is $11.00 from Roanna Ruiz at SVB Leerink, which represents a 213.8% increase from the current price of $3.51.
What is the overall SCPH consensus from analysts for ScPharmaceuticals Inc.?
The overall analyst consensus for SCPH is bullish. Out of 9 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $12.50.
How accurate are SCPH stock price projections?
Stock price projections, including those for ScPharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 7:44 AM UTC